OTLK logo

Outlook Therapeutics, Inc. Common Stock


OTLK: Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications.


Show OTLK Financials

Consumer Interest
SEC Filings

Recent trades of OTLK by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard

Recently reported changes by institutional investors

Quarterly net insider trading by OTLK's directors and management

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Buffer formulations for enhanced antibody stability Mar. 29, 2022
  • Patent Title: Modulation of charge variants in a monoclonal antibody composition Jun. 30, 2020
  • Patent Title: Buffer formulations for enhanced antibody stability Aug. 13, 2019
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard

Number of mentions of OTLK in WallStreetBets Daily Discussion


Recent insights relating to OTLK

CNBC Recommendations

Recent picks made for OTLK stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in OTLK

Corporate Flights

Flights by private jets registered to OTLK